Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
The Parsippany, New Jersey-based firm expects to expand relationships with multiple biopharmaceutical companies after bolstering its biopharma services business.